ライフサイエンスコーパス: MSP-1

1 n 1 (AMA-1) and merozoite surface protein 1 (MSP-1).

2 elated protein, merozoite surface protein-1 (MSP-1).

3 ional monoclonal antibodies against P. vivax MSP-1.

4 g peptide-specific T cells recognized native MSP-1.

5 rs against the immunogen as well as parasite MSP-1.

6 subjects seroconverted to homologous CSP and MSP-1.

7 ctivation of the prometastatic growth factor MSP-1.

8 MSP-1#1 stimulated T-cell responses in three of the six

9 s showed that one highly conserved sequence (MSP-1#1, VTHESYQELVKKLEALEDAV; located at amino acid pos

10 e immunoassay with six different recombinant MSP-1(19) Ags did not correlate with protection from inf

11 area, whereas T cells responded to all four MSP-1(19) alleles evaluated.

12 is to change specific amino acid residues in MSP-1(19) and abolish antibody binding, and by using PEP

13 1(19) antibody levels, individuals with anti-MSP-1(19) antibodies that compete with an invasion inhib

14 fection primed the production of anti-native MSP-1(19) antibodies, which were boosted by vaccination

15 except that, after correcting for total anti-MSP-1(19) antibody levels, individuals with anti-MSP-1(1

16 are predominantly IgG3 whereas antibodies to MSP-1(19) are mainly IgG1.

17 detectable IgG and IgM Abs to MSP-1(42) and MSP-1(19) at 6 mo of age with no significant change by a

18 sites/microl of blood) were seronegative for MSP-1(19) at the time of infection.

19 nvasion inhibitory activity of antibodies to MSP-1(19) but find no significant association between an

20 In contrast, high levels of MSP-1(19) IgG or IgG subclass Abs measured by enzyme imm

21 of 5 of 86 (6%) newborns had cord blood anti-MSP-1(19) IgM Abs, an Ig isotype that does not cross the

22 showed the greatest age-related increase in MSP-1(19) IIA compared with infants with prenatal exposu

23 In contrast, MSP-1(19) IIA levels increased from 6 to 24-30 mo of age

24 Abs against the MSP-1(19) merozoite ligand (MSP-1(19) IIA).

25 est that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be

26 mine the potential protective role of Abs to MSP-1(19) in individuals naturally exposed to malaria, w

27 cells that produced IgG when stimulated with MSP-1(19) in vitro.

28 ther of the two allelic forms of recombinant MSP-1(19) induced high levels of antigen-specific Th1 (g

29 antifies invasion inhibition Abs against the MSP-1(19) merozoite ligand (MSP-1(19) IIA).

30 nic P. falciparum expressing the P. chabaudi MSP-1(19) orthologue, individuals with high-level MSP-1(

31 fection, and suggest that the measurement of MSP-1(19) specific inhibitory Abs may serve as an accura

32 A comparison of MSP-1(19) structures from P. knowlesi, P. cynomolgi, and

33 of the C-terminal domains of MSP-1 (known as MSP-1(19)) from Plasmodium knowlesi.

34 tein of the major merozoite surface protein (MSP-1(19)) fused to tetanus toxoid universal T-cell epit

35 dium falciparum merozoite surface protein-1 (MSP-1(19)) is a target of protective Abs against blood-s

36 to the C-terminal 19-kDa fragment of MSP-1 (MSP-1(19)) were detected in 24 of 92 (26%) newborns (4-1

37 f P. falciparum merozoite surface protein 1 (MSP-1(19)), a major blood stage vaccine candidate, is th

38 d 19-kilodalton merozoite surface protein 1 (MSP-1(19))-specific erythrocyte invasion inhibitory acti

39 g 33 kDa and 19 kDa fragments (MSP-1(33) and MSP-1(19)).

40 pidermal growth factor domains that comprise MSP-1(19), and are classified as either inhibitory (inhi

41 In this phase I trial of MSP-1(19), immunization of nonexposed human volunteers w

42 pped onto the three-dimensional structure of MSP-1(19), it was apparent that the epitopes for the mAb

43 ts and recombinant circumsporozoite antigen, MSP-1(19), MSP-2, AMA-1, and Pf155 (also called ring-inf

44 onses were restricted to the Q-KNG allele of MSP-1(19), the major variant in this endemic area, where

45 To map protein binding surfaces on MSP-1(19), we have analyzed the crystal contacts in five

46 s implicate an important protective role for MSP-1(19)-specific invasion inhibitory Abs in immunity t

47 (19) orthologue, individuals with high-level MSP-1(19)-specific invasion-inhibitory Abs (>75th percen

48 ary processing of MSP-1(42) to MSP-1(33) and MSP-1(19).

49 a significantly higher response to P. vivax MSP-1(19).

50 f the six strains of mice evaluated, whereas MSP-1#23 was immunogenic in only one strain.

51 20 to 39) and one partly conserved sequence (MSP-1#23, GLFHKEKMILNEEEITTKGA; located at positions 44

52 sing, producing 33 kDa and 19 kDa fragments (MSP-1(33) and MSP-1(19)).

53 hibited secondary processing of MSP-1(42) to MSP-1(33) and MSP-1(19).

54 subjects remained seropositive to homologous MSP-1(42) >5 months after CHMI.

55 luble and refolded forms of the P. cynomolgi MSP-1(42) (PcMSP-1(42)) proteins.

56 ethod for the production of Plasmodium vivax MSP-1(42) (PvMSP-1(42)) as a soluble protein.

57 as either inhibitory (inhibit processing of MSP-1(42) and erythrocyte invasion), blocking (block the

58 Infants had detectable IgG and IgM Abs to MSP-1(42) and MSP-1(19) at 6 mo of age with no significa

59 ed monkeys inhibited secondary processing of MSP-1(42) to MSP-1(33) and MSP-1(19).

60 The Abs to AMA-1 and MSP-1(42) were predominantly IgG1 and IgG3.

61 fragment of the merozoite surface protein 1 (MSP-1(42)) is a leading candidate for the development of

62 dium falciparum merozoite surface protein 1 (MSP-1(42)) is a prime candidate for a blood-stage malari

63 erythrocyte invasion one of these of 42 kDa (MSP-1(42)) is subjected to a second processing, producin

64 kDa fragment of merozoite surface protein 1 (MSP-1(42)) of P. vivax and P. falciparum using an enzyme

65 e P. falciparum merozoite surface protein 1 (MSP-1(42)) using the most frequently occurring codon in

66 minal region of merozoite surface protein 1 (MSP-1(42)), a B epitope of ring-infected erythrocyte sur

67 al processing fragment of P. chabaudi MSP-1 (MSP-1(42)).

68 al Ags, with 53% having IgG to AMA-1, 38% to MSP-1(42), 3% to RESA, and 0% to CSP.

69 onstrated reactivity to heterologous CSP and MSP-1(42), and a similar proportion of subjects remained

70 pon challenge with P. cynomolgi, none of the MSP-1(42)-vaccinated groups demonstrated sterile protect

71 ains that may function similarly to those of MSP-1(42).

72 the antibodies with every octapeptide within MSP-1(42).

73 lasmodium vivax merozoite surface protein 1 (MSP-1) 42-kDa fragment (PvMSP-1 p42) is a promising vacc

74 asmodium yoelii merozoite surface protein-1 (MSP-1), a leading vaccine candidate against erythrocytic

75 h correlates with infant development of anti-MSP-1 Abs acquired as a consequence of natural malaria i

76 work indicates that MT-SP1 is sufficient for MSP-1 activation and that MT-SP1, MSP-1, and the previou

77 epitopes in the N-terminal block 3 region of MSP-1 also drove IFN-gamma and/or IL-13 production.

78 of antibodies to two P. falciparum antigens (MSP-1, AMA-1).

79 immunoglobulin G (IgG) to Pf-stage-specific MSP-1, AMA-1, GLURPR0, LSA-1, and CSP.

80 MSP-1, an indispensable antigen critical for invasion an

81 MOI estimates were derived by PCR at the msp-1 and -2 loci.

82 on with its key parasite protein substrates, MSP-1 and alpha-tubulin-I.

83 trast, antibody levels to and frequencies of MSP-1 and EBA-175 were similar in adults in areas of sta

84 tubes and AMB-1 via the cell surface protein MSP-1 and flagellin.

85 vestigated various microsatellites alongside msp-1 and msp-2 for molecular correction and compared di

86 However, suitable combinations with msp-1 and msp-2, as well as the performance of different

87 ody response and the concurrent targeting of MSP-1 and MSP-8 resulted in improved, nearly complete pr

88 nding of the protective antibody response to MSP-1 and of immune evasion by antigenic diversion.

89 ii MSRP-2 with the amino-terminal portion of MSP-1 and with each other on the surface of schizonts.

90 manifests positive natural selection for the MSP-1 and, less strongly, MSP-3 polymorphisms; the McDon

91 orders, such as MultiSystem Proteinopathy 1 (MSP-1) and Familial Amyotrophic Lateral Sclerosis (ALS).

92 n of the 3D7 Pf merozoite surface protein-1 (MSP-1), and tetanus toxoid were measured by indirect enz

93 tigenic genes of P. falciparum (such as Csp, Msp-1, and Msp-2) exhibit numerous polymorphisms that ha

94 enes known to be extremely polymorphic: Csp, Msp-1, and Msp-2.

95 ce parasitemic, stronger responses to AMA-1, MSP-1, and MSP-3 were associated with protection (odds r

96 ion in the genes encoding AMA-1, CSP, LSA-1, MSP-1, and Pfs48/45.

97 icient for MSP-1 activation and that MT-SP1, MSP-1, and the previously shown MSP-1 tyrosine kinase re

98 ntibodies and B -0.26; -0.41, -0.11 for anti-MSP-1 antibodies.

99 as associated with lower anti-AMA-1 and anti-MSP-1 antibody levels in pooled analyses adjusted for ag

100 a malaria vaccine antigen and antibodies to MSP-1 are associated with protection from disease.

101 that naturally induced human Ab responses to MSP-1 are short lived.

102 dium falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical m

103 need to consider these factors in evaluating MSP-1 as a vaccine component.

104 est that fetal sensitization or tolerance to MSP-1, associated with maternal malaria infection during

105 f sequence diversity in genes encoding three MSP-1-associated surface antigens of P. falciparum, rang

106 ibitor blocked the proteolytic activation of MSP-1 at the cell surface of peritoneal macrophages.

107 dium falciparum merozoite surface protein-1 (MSP-1) at birth correlates with infant development of an

108 The MSP-1-based polypeptide, BVp42, corresponds to the 42-kD

109 These may be suitable for the development of MSP-1-based vaccines against malaria.

110 djuvants and delivery systems for AMA-1- and MSP-1-based vaccines can be selected for their ability t

111 However, MSP-1-based vaccines performed poorly in clinical trials

112 orrelate of protection in clinical trials of MSP-1-based vaccines.

113 MSP-1 Block2 genotypes were used to estimate the complex

114 by a direct effect of antibodies against the MSP-1 C-terminal region.

115 t two sequences located in the N terminus of MSP-1 can induce T- and B-cell responses following immun

116 s biochemically isolated as part of the shed MSP-1 complex.

117 In utero sensitization to MSP-1 correlated with the presence of malaria parasites

118 mbrane-bound proteinase in the processing of MSP-1 during erythrocyte invasion.

119 he development of functional Ab responses to MSP-1 during infancy.

120 e leishmanolysin gene, Entamoeba histolytica MSP-1 (EhMSP-1) and EhMSP-2, while the commensal ameba E

121 n of photosystem II in Arabidopsis thaliana, MSP-1 (encoded by psbO-1, At5g66570), and MSP-2 (encoded

122 fragment of the merozoite surface protein 1 (MSP-1) from Plasmodium falciparum has been determined us

123 l region of the merozoite surface protein-1 (MSP-1) from the rodent malarial parasite Plasmodium yoel

124 Immunity to MSP-1 has been implicated in protection against infectio

125 dium falciparum merozoite surface protein 1 (MSP-1) has been evaluated in Aotus lemurinus griseimembr

126 act with the amino-terminal end of P. yoelii MSP-1 in a yeast two-hybrid system.

127 longitudinal patterns of IgG Ab responses to MSP-1 in individuals.

128 ymorphic region and to a conserved region of MSP-1 in three cohorts of African villagers exposed to P

129 ability of MT-SP1 to cleave and activate pro-MSP-1 in vitro and in a cellular context.

130 otection induced by the carboxyl terminus of MSP-1 in vivo and illustrate the need to consider these

131 AMA-1) and merozoite surface antigen 1 (anti-MSP-1) in cross-sectional and longitudinal studies.

132 o P. falciparum merozoite surface protein-1 (MSP-1) in infants born in an area of stable malaria tran

133 However, MSP-1 is a polymorphic protein and its immune recognitio

134 port a conclusion that the block 2 region of MSP-1 is a target of protective immunity against P. falc

135 MSP-1 is initially processed into smaller fragments; and

136 Merozoite Surface Protein 1 (MSP-1) is a malaria vaccine antigen and antibodies to MS

137 Merozoite surface protein 1 (MSP-1) is a precursor to major antigens on the surface o

138 The major merozoite surface protein 1 (MSP-1) is currently a leading vaccine candidate antigen.

139 t the structure of the C-terminal domains of MSP-1 (known as MSP-1(19)) from Plasmodium knowlesi.

140 ween the two measures, particularly with the msp-1 locus (P = 5.92x10(-5)).

141 sponses to the C-terminal 19-kDa fragment of MSP-1 (MSP-1(19)) were detected in 24 of 92 (26%) newbor

142 -terminal processing fragment of P. chabaudi MSP-1 (MSP-1(42)).

143 sponse specific for major surface protein 1 (MSP-1), MSP-2, and MSP-3.

144 nds genotyping polymorphic markers including msp-1, msp-2, and glurp for distinguishing recrudescence

145 ntification of the helper T-cell epitopes on MSP-1, MSP-2, and MSP-3 that are needed to evoke anamnes

146 rozoite or the merozoite (AMA-1, CSP, LSA-1, MSP-1, MSP-2, and MSP-3) are more polymorphic than those

147 alves included major surface proteins (MSPs) MSP-1, MSP-2, and MSP-3, which were previously shown to

148 xpression decreased, while the expression of msp-1, msp-7, and several rhoptry protein genes increase

149 aluated by PCR that targeted the polymorphic msp-1/msp-2 alleles.

150 The msp-1/msp-2/2490 combination identified more recrudescen

151 ether-lumefantrine (AL) treatment arm, while msp-1/msp-2/glurp combination classified more cases of r

152 imensional structure by considering specific MSP-1 mutants.

153 Merozoite surface protein-1 (MSP-1) of Plasmodium falciparum is a malaria vaccine can

154 cted to the major merozoite surface protein (MSP-1) of this parasite enabled both BALB/cByJ mice and

155 been shown to be extrinsically associated to MSP-1 on the parasite surface.

156 Immunization with either MSP-1 or MSP-8 induces protection that is mediated prima

157 onses to PHA, PPD, and Plasmodium falciparum MSP-1 peptides did not significantly differ by age.

158 roduced one or more cytokines in response to MSP-1, PfP0, and EBA-175, respectively.

159 PC2 scores were correlated with MSP-1 positively (R = 0.52, P < 0.001) and CSP negativel

160 Unlike MSP-1, PyMSP-8-dependent protection required immunizatio

161 verse neutralizing potential in complex with MSP-1 revealed the epitope of a potent strain-transcendi

162 dy responses to merozoite surface protein-1 (MSP-1), ribosomal phosphoprotein P0 (PfP0), and region I

163 to malaria but who lacked detectable T cell MSP-1 sensitization.

164 ) and P. yoelii merozoite surface protein-1 (MSP-1) showed encouraging results when tested individual

165 cord blood lymphocyte cytokine responses to MSP-1) showed the greatest age-related increase in MSP-1

166 Lower AMA-1 and MSP-1-specific antibody levels persisted over time in ir

167 This enhanced MSP-1-specific antibody response and the concurrent targ

168 Certain MSP-1-specific monoclonal antibodies (mAbs) react with c

169 Here, we investigated a panel of MSP-1-specific naturally acquired human monoclonal antib

170 -1-specific rodent antibody was disrupted by MSP-1-specific non-inhibitory blocking/interfering antib

171 chanism wherein parasite neutralization by a MSP-1-specific rodent antibody was disrupted by MSP-1-sp

172 Effective priming of MSP-1-specific T cells was also demonstrated in lymphocy

173 es in response to MA and a pool of conserved MSP-1 T cell epitopes.

174 city of conserved and polymorphic regions of MSP-1, the specificity of Ab responses to a polymorphic

175 MT-SP1 induced the ability of MSP-1 to inhibit nitric oxide production in bone marrow

176 that MT-SP1, MSP-1, and the previously shown MSP-1 tyrosine kinase receptor RON are required for peri

177 ation and enhanced production of antibody to MSP-1 upon exposure to merozoites.

178 ollowing an initial rise in parasitemia, all MSP-1-vaccinated animals had significantly lower parasit

179 and 19-kDa C-terminal processed fragments of MSP-1 were determined by serology and by a functional as

180 rom conserved or partly conserved regions of MSP-1 were evaluated for immunogenicity in B10 congenic

181 oliferate in vitro and antibody responses to MSP-1 were evaluated in vivo.

182 Antibodies to the block 2 region of MSP-1 were measured in a cohort of 280 children before t

183 Ags from the polymorphic Block 2 region of MSP-1 were recognized by many, although not all individu

184 of the major polymorphic region (Block 2) of MSP-1 were used to determine the specificity and longitu

185 (EBA-175), and merozoite surface protein 1 (MSP-1) were compared in 243 Kenyans living in a highland

186 target for inhibitors of protein binding to MSP-1, which might prevent invasion of the merozoite int